OptimizeRx Corp. (NASDAQ:OPRX) Given Consensus Recommendation of “Moderate Buy” by Analysts

OptimizeRx Corp. (NASDAQ:OPRX) has earned a consensus rating of “Moderate Buy” from the nine ratings firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, six have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $17.5714.

A number of equities analysts recently issued reports on OPRX shares. Zacks Research upgraded OptimizeRx from a “hold” rating to a “strong-buy” rating in a report on Friday, March 13th. Roth Mkm decreased their target price on OptimizeRx from $32.00 to $18.00 and set a “buy” rating for the company in a research report on Friday, March 6th. Stifel Nicolaus lowered their price target on OptimizeRx from $21.00 to $17.00 and set a “buy” rating on the stock in a report on Friday, March 6th. B. Riley Financial reiterated a “buy” rating and set a $11.00 price target (down from $28.00) on shares of OptimizeRx in a report on Friday, March 6th. Finally, Stephens lowered their price target on OptimizeRx from $17.00 to $10.00 and set an “equal weight” rating on the stock in a report on Friday, March 6th.

OptimizeRx Stock Performance

Shares of NASDAQ OPRX opened at $6.14 on Thursday. The company has a quick ratio of 3.04, a current ratio of 3.04 and a debt-to-equity ratio of 0.17. The stock has a market capitalization of $115.20 million, a price-to-earnings ratio of 23.62 and a beta of 1.28. The stock’s fifty day simple moving average is $6.79 and its 200 day simple moving average is $11.65. OptimizeRx has a 52-week low of $5.54 and a 52-week high of $22.25.

OptimizeRx (NASDAQ:OPRX) last issued its earnings results on Saturday, January 31st. The company reported $0.51 earnings per share (EPS) for the quarter. OptimizeRx had a return on equity of 10.61% and a net margin of 4.69%. As a group, sell-side analysts forecast that OptimizeRx will post 0.5 earnings per share for the current fiscal year.

OptimizeRx declared that its Board of Directors has authorized a share repurchase plan on Thursday, March 5th that allows the company to buyback $10.00 million in outstanding shares. This buyback authorization allows the company to buy up to 6.8% of its stock through open market purchases. Stock buyback plans are usually a sign that the company’s management believes its stock is undervalued.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. CenterBook Partners LP purchased a new position in shares of OptimizeRx during the third quarter valued at $6,331,000. State of Alaska Department of Revenue purchased a new position in shares of OptimizeRx during the fourth quarter valued at $62,000. Harbor Capital Advisors Inc. grew its holdings in shares of OptimizeRx by 12.2% during the fourth quarter. Harbor Capital Advisors Inc. now owns 24,876 shares of the company’s stock valued at $305,000 after buying an additional 2,708 shares in the last quarter. Granahan Investment Management LLC purchased a new position in shares of OptimizeRx during the third quarter valued at $1,456,000. Finally, Integrated Quantitative Investments LLC purchased a new position in shares of OptimizeRx during the third quarter valued at $379,000. Hedge funds and other institutional investors own 76.47% of the company’s stock.

About OptimizeRx

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.